Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
07 Sep 2006 Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial of Anti-C. difficile Antibody Combination for the Treatment of Hospital Acquired Diarrhea
05 Sep 2006 Protherics Plc announces Publication of CytoFab(R) Phase 2b Data in Leading Journal
29 Aug 2006 Genentech and Biogen Idec Announce Positive Results from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
23 Aug 2006 Medarex and GenPat77 Announce Therapeutic Antibody Co-Development Agreement
22 Aug 2006 MedImmune Files Investigational New Drug Application for MT103
18 Aug 2006 MorphoSys Obtains PER.C6® Human Cell Line for Production of Antibody Material in MOR103 Program
18 Aug 2006 New Data Confirm Durable Response of TNX-355 Regimens Through 48 Weeks in Treatment-Experienced HIV Patients
18 Aug 2006 OMRIX Biopharmaceuticals Announces U.S. Phase III Clinical Trial for Intravenous Immunoglobulin (IVIG) in Subjects with Primary Immune Deficiency Diseases
16 Aug 2006 Raven Presents Preliminary Clinical Results From Phase 1 Study of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
16 Aug 2006 Chromos Updates On Progress with Development of CHR-1103 For Treatment of MS
15 Aug 2006 FDA Expands REMICADE(R) (Infliximab) Psoriatic Arthritis Indication: Anti-TNF Shown to Inhibit Joint Damage and Improve Physical Function
12 Aug 2006 Genentech Provides Update On Supplemental Biologics License Application For Adjuvant Herceptin® In Early-Stage Her2-Positive Breast Cancer
09 Aug 2006 Human Genome Sciences Announces Phase 3 Clinical Development Program For Lymphostat-B(TM) In Systemic Lupus Erythematosus
08 Aug 2006 Avastin filed in Europe for treatment of most common form of lung cancer
04 Aug 2006 Tanox Conducts Meeting with Food and Drug Administration Regarding its HIV/AIDS Antibody, TNX-355
02 Aug 2006 Taligen Therapeutics Announces Successful Achievement of Series A Milestone
01 Aug 2006 Ono and Medarex Announce Allowance of Investigational New Drug Application for MDX-1106 for the Treatment of Cancer
31 Jul 2006 YM Biosciences Licenses Monoclonal Antibody, Nimotuzumab, To Daiichi Pharmaceutical For Japan
31 Jul 2006 Abbott's HUMIRA® (adalimumab) Receives FDA Approval for Treatment of Ankylosing Spondylitis
31 Jul 2006 Avastin and Xeloda meet primary endpoints in large Phase III first line metastatic colorectal cancer study
27 Jul 2006 Cambridge Antibody Technology Announces Acquisition of Oncology Product Candidate From Enzon
25 Jul 2006 Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants
25 Jul 2006 ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus
24 Jul 2006 Biogen Idec and Elan Announce Availability of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis
24 Jul 2006 MedImmune and Micromet Report on Novel Anti-cancer BiTE®
24 Jul 2006 Serono Initiates First Lage Scale European Pharmaco-Epidemiological Study in Psoriasis to Further Document the Demonstrated Long-Term Safety Profile of Raptiva®
21 Jul 2006 Biocon gets DCGI nod for cancer drug
21 Jul 2006 XTL Provides Update on HepeX-B Program
20 Jul 2006 Human Genome Sciences Initiates Randomized Phase 2 Clinical Trial of HGS-ETR1 in Combination With Bortezomib
20 Jul 2006 ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
19 Jul 2006 Trans Genic and Kumamoto Foundation Conclude Anti-HIV Antibody License Agreement
19 Jul 2006 CIMZIA(TM) Shows Promise in Treatment of Psoriasis
18 Jul 2006 Lpath Creates First Neutralizing Monoclonal Antibodies Against LPA, an Important Cancer Target
14 Jul 2006 Nabi Biopharmaceuticals Receives Positive Opinion from FDA Blood Products Advisory Committee for Nabi-HB Intravenous
12 Jul 2006 IQ Corporation Announces Key Milestone in Development of Anthrax Monoclonal Antibody Treatments
11 Jul 2006 Alfacell Corporation Announces New Research Collaboration to Develop Next-Generation Targeted Therapies for Cancer
11 Jul 2006 MabThera approved in Europe for maintenance therapy in patients with common form of lymphoma
11 Jul 2006 MabThera approved for use in rheumatoid arthritis in Europe
10 Jul 2006 Avastin filed in Europe for first-line treatment of women with advanced breast cancer
10 Jul 2006 Takeda and Galaxy Biotech Sign License Agreement for Galaxy's Investigational Antibodies for the Treatment of Cancer
10 Jul 2006 Genmab Initiates Ofatumumab (Humax-CD20) Pivotal Study In NHL
06 Jul 2006 MediGene and German Cancer Research Center to Develop Antibody against Ovarian Cancer
01 Jul 2006 FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
30 Jun 2006 Inhibitex Announces Results Of MSCRAMM(R) Platform Review
29 Jun 2006 Nabi Biopharmaceuticals Secures Agreement with Kedrion to Co-Develop and Commercialize Civacir in Europe
29 Jun 2006 TYSABRI (R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis
29 Jun 2006 Alexion Reports Phase III Preliminary Results for APEX-AMI Study
27 Jun 2006 Euroscreen and Medarex Announce License and Research Service Agreement
27 Jun 2006 Phase III Study of Avastin in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
26 Jun 2006 Abbott Receives FDA Approval for New HUMIRA(R) Delivery Device
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
Results 901 - 950 of 1157

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics